Cost-benefit issues about human papillomavirus (HPV) testing.
- Author:
Sokbom KANG
1
Author Information
1. National Cancer Center, Goyang, Korea. sokbom@ncc.re.kr
- Publication Type:Review
- Keywords:
Cervical neoplasm;
Human papillomavirus;
Cancer screening;
Cost-effectiveness;
Vaccine;
Cancer prevention
- MeSH:
Cost-Benefit Analysis;
Early Detection of Cancer;
Humans*;
Mass Screening;
Uterine Cervical Neoplasms
- From:Korean Journal of Gynecologic Oncology
2006;17(3):183-187
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recently, a number of evidences that human papillomavirus (HPV) testing was efficient in cervical cancer screening were introduced. Moreover, successful trial outcome of preventive cancer vaccine opened new era of cervical cancer prevention. However, undoubtedly, applying new cancer screening and prevention strategy would bring on economical concern about increased medical expense. Therefore, appropriate cost-benefit analysis is very important before establishing new strategy as standard policy. In this article, we presented a few recent results about cost-benefit effectiveness by other group. And we also suggested what would be needed to perform successful.
